US 12,226,604 B2
Dual pathway therapeutic agent delivery
Aravind Arepally, Atlanta, GA (US); James E. Chomas, Denver, CO (US); David Benjamin Jaroch, Arvada, CO (US); and Patrick Charles McCain, Denver, CO (US)
Assigned to TriSalus Life Sciences, Inc., Westminster, CO (US)
Filed by TriSalus Life Sciences, Inc., Westminster, CO (US)
Filed on May 19, 2022, as Appl. No. 17/749,061.
Application 17/749,061 is a continuation of application No. 16/405,605, filed on May 7, 2019, granted, now 11,338,117.
Claims priority of provisional application 62/742,573, filed on Oct. 8, 2018.
Prior Publication US 2022/0273920 A1, Sep. 1, 2022
Int. Cl. A61M 39/02 (2006.01); A61M 25/00 (2006.01); A61M 31/00 (2006.01); A61M 5/142 (2006.01)
CPC A61M 31/002 (2013.01) [A61M 25/0026 (2013.01); A61M 5/14276 (2013.01); A61M 39/0208 (2013.01)] 38 Claims
OG exemplary drawing
 
1. A method of delivering a treatment therapy to a patient, the treatment therapy to treat an organ diagnosed with a disease state, comprising:
a) delivering a first therapeutic agent into systemic circulation at a first flow rate; and
b) delivering a second therapeutic agent directly into or adjacent a vessel extending from the organ at a higher second flow rate than the first flow rate in a manner that provides targeted treatment of the organ.